The implant comes with a new, lower profile delivery System that allows for smaller incisions in preparation for delivery. More from the an**uncement:
Data from 100 patients in the CADENCE-MIS trial, a randomized, controlled, multi-center trial comparing minimally-invasive AVR with the Edwards INTUITY Valve System to full ster**tomy AVR with any conventional bioprosthetic Aortic valve, were recently presented at the 2014 Annual Meeting of the Society of Thoracic Surgeons (STS). The trial found:
Minimally-invasive AVR with the Edwards INTUITY platform demonstrated a statistically significant reduction (24 percent) in ischemic time (the amount of time blood flow to and from the heart is stopped during surgery) compared to the full ster**tomy approach with conventional bioprosthetic valves. These results are especially meaningful as minimally-invasive approaches have traditionally been associated with longer ischemic times; and
Improved blood flow and hemodynamics with the Edwards INTUITY Valve compared to conventional bioprosthetic valves at 3-month follow-up.
Additionally, an interim analysis of 158 patients undergoing isolated Aortic Valve replacement in the prospective, multicenter, single-arm TRITON Trial(1) for the Edwards INTUITY platform, found that 55 percent were performed through a Minimally Invasive approach, as opposed to a full ster**tomy.
04-05-2014, 01:14 AM
Edwards INTUITY Elite Minimally Invasive Aortic Valve System Green Lighted in Europe
Edwards Lifesciences just received CE Mark approval for its new INTUITY Elite Aortic Valve prosthesis. The device utilizes a balloon-expandable frame with the firm’s 25-year-old Carpentier-Edwards*pericardial PERIMOUNT platform.
العرض العادي
